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We examined pre-mobilization blood CD34
þ cell count to predict ability to mobilize adequate peripheral blood progenitor cells (PBPC) in 106 cancer patients and 36 allogeneic donors. Mean pre-mobilization therapy blood CD34
þ cell count was 3.1 cells Â 10 6 /l (s.d. ¼ 3.9, r ¼ 0. and mean CD34 /l (r ¼ 0.37, P-valueo0.0001); correlation was stronger in allogeneic donors (r ¼ 0.56, Pvalue ¼ 0.0004) and males (r ¼ 0.46, P-valueo0.0001). Based on classification and regression tree multivariate analysis, the predictive value of pre-mobilization blood CD34 þ cell count was confounded by other variables, including age, gender, mobilization regimen and malignancy type. We generated an algorithm to predict a minimum PBPC yield of 1 Â 10 6 CD34 þ cells/kg/ leukapheresis procedure after mobilization. A threshold pre-mobilization blood CD34 þ cell count of 2.65 cells Â 10 6 /l was the most important decision point in predicting successful mobilization. Only 2% of subjects with pre-mobilization blood CD34 þ cell counts 42.65 cells Â 10
Introduction
Mobilized peripheral blood progenitor cells (PBPC) are routinely used for both autologous and allogeneic hematopoietic stem cell transplantation. 1 The ability to collect adequate numbers of PBPC is a prerequisite for this procedure. In general, infusion of X2.5 Â 10 6 CD34 þ cells/ kg is sufficient for prompt blood cell recovery after myeloablative therapy. [2] [3] [4] Sufficient numbers of PBPC can be collected with either cytokines alone or a combination of cytotoxic chemotherapy and growth factors. 5, 6 Several studies have shown, however, that 20-50% of patients fail to mobilize sufficient numbers of hematopoietic progenitors for collection. [7] [8] [9] Of this group of patients, often referred to as 'poor mobilizers', 15-30% were unable to proceed to transplantation. 7, 9 Factors predicting poor mobilization include: extensive prior chemotherapy 10 or radiation therapy 10, 11 as well as marrow involvement with malignancy. 5, 6 Similarly, 10% of allogeneic donors given granulocyte-colony-stimulating factor (G-CSF) as the mobilization stimulus will have poor mobilization of hematopoietic progenitors. 12, 13 This observation in allogeneic donors suggests that factors other than malignancy and prior therapy may affect mobilization.
We performed a retrospective analysis to identify if pre-mobilization therapy blood CD34 þ cell count is predictive of the ability to mobilize adequate numbers of CD34 þ cells in both patients and allogeneic donors. We reasoned that pre-mobilization therapy blood steadystate CD34 þ cell count would represent a surrogate marker for hematopoietic stem cell reserve and would correlate with leukapheresis yield. Predictions for a successful stem cell mobilization ideally should be made before initiating any mobilization procedure in order to spare those with a low chance of success from the toxicity and risks associated with the mobilization regimen and procedure. In addition to blood CD34 þ cell count, we used patient diagnosis, age, gender and type of mobilization regimen to generate a classification and regression tree (CART) analysis and developed a simple algorithm to identify prospectively individuals at risk for poor mobilization.
Materials and methods

Study population
Patients aged 2-70 years with a histologic diagnosis of Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, acute myeloid leukemia, acute lymphocytic leukemia or solid tumor diagnosis (breast cancer, sarcoma, testicular cancer, brain cancer and choriocarcinoma) who were eligible for autologous PBSC transplant were analyzed. Also, allogeneic donors aged 5-62 years evaluated for sibling-matched allogeneic PBSC transplant were included in the analysis. All subjects were evaluated and treated at the University Hospitals of Cleveland from October 2000 to October 2002.
Mobilization and collection of PBPC Steady-state blood CD34 þ cell count was obtained at the time of initiating mobilization therapy, at least 4 weeks after the last exposure to chemotherapy or radiation therapy.
Patients with malignancy were treated using five different mobilization regimens: cyclophosphamide 4 g/m 2 intravenously (i.v.) on the first day with mesna uroprotectant and G-CSF 10 mg/kg/day subcutaneously (s.c.) beginning between 36 and 48 h after completion of cyclophosphamide and continuing until the last day of leukapheresis; cyclophosphamide 4 g/m 2 i.v. on the first day with mesna uroprotectant and etoposide 200 mg/m 2 i.v. on days 1, 2 and 3 and G-CSF 10 mg/kg/day s.c. beginning 24-36 h after completion of etoposide and continuing until the last day of leukapheresis; disease-specific chemotherapy and G-CSF 10 mg/kg/day s.c. beginning 24 h after completion of chemotherapy and continuing until the last day of leukapheresis; G-CSF 5 mg/kg/day s.c. and GM-CSF 5 mg/ kg/day s.c. continuing until the last day of leukapheresis; and single-agent G-CSF 10 mg/kg/day s.c. continuing until the last day of leukapheresis. All allogeneic donors underwent mobilization therapy with G-CSF 10 mg/kg/day s.c. continuing until the last day of leukapheresis.
The first apheresis procedure was initiated when the white blood cell (WBC) count exceeded 3.0 Â 10 9 /l and platelet count above 20.0 Â 10 9 /l after the mobilization regimen. Allogeneic donors began leukapheresis on day 5 of G-CSF administration. PBPC were collected using standard leukapheresis procedures (COBE SPECTRA, Lakewood, CO, USA). The target for the leukapheresis was to process 10-15 l of whole blood (three patient blood volumes) in each session. The goal was to collect a minimum total (for all apheresis procedures) of 2.5 Â 10 6 CD34 þ cells/kg. For analysis purposes, a successful leukapheresis was defined as one containing a minimum of 1 Â 10 6 CD34 þ cells/kg. The number of post-mobilization CD34
þ cells collected was a total of all leukaphereses procedures.
CD34
þ cell enumeration and flow cytometry CD34 þ cell enumeration was carried out on both blood and apheresis products using a modified International Society of Hematotherapy and Graft Engineering protocol with a gating procedure and acquisition strategy similar to that described previously. 14, 15 Briefly, 200 ml of whole blood, or 100 ml of leukapharesis product was stained with 20 ml of CD34 þ -phycoerythrin (BD BioSciences, San Diego, CA, USA) and 20 ml of CD45-fluorescein isothiocyanate (BD BioSciences) as described by the manufacturer and analyzed on a FACSCalibur flow cytometer (BD, Biosciences). Blood or product was diluted with Rosewell park memorial institute medium and 10% fetal calf serum to a final WBC count of 10 Â 10 9 /l before staining, if necessary. Two fifty thousand total events were acquired with a CD45 fluorescence threshold of 400 and forward scatter threshold of 200 to exclude debris and non-viable elements. The percentage of CD34 þ cells was determined using Paint-a-gate software (BD BioSciences) by highlighting the CD34 þ moderate to brightly positive cells with low side scatter on the CD34 þ Â SSC dot plot and the CD34 þ , CD45 þ (dim to moderate) cells on the CD45 Â CD34 dot plot. Final CD34 þ cell percentage was determined relative to isotype controls. The total CD34 þ cells were calculated by multiplying the percentage of CD34 þ cells by the peripheral blood white count or total number of nucleated cells in the apheresis product determined on a Sysmex XE-2100 (Sysmex, Kobe, Japan). Harvested cells from each leukapheresis collection were analyzed for CD34 þ cells using flow cytometric analysis. A representative example is shown in Figure 1 .
Statistical methods
The correlation between two measurements (pre-mobilization CD34 þ cells/ml and post-mobilization CD34 þ cells/ kg/leukapheresis) and different variables was estimated using the Spearman's correlation coefficient. CART analysis was used to develop an algorithm to predict an adequate CD34 þ cell collection, defined as X1 Â 10 6 CD34 þ cells/ kg/leukapheresis procedure. 16, 17 CART analysis has many advantages over more traditional methods (a few assumptions are required) and can reveal complex interactions (or patterns) that may exist in the data set. The CART is a recursive partitioning method that uses a tree model to separate a heterogeneous group into smaller, more homogenous groups that are defined by impurity. We implemented CART analysis using Splus (Insightful Corporation, Seattle, WA, USA). In the Splus methodology, 17 the impurity of each node (group) i is measured by the deviance, which is defined as
where p ik is the probability distribution over the classes. In our case, there are two classes, that is,
The deviance of a whole classification tree is defined as
as a sum over all leaves (terminal nodes). Clearly for each node, if all samples in the node are the same type (homogeneous), then its deviance reaches CD34 þ blood count and mobilization efficacy P Fu et al minimum 0 and its deviance reach maximum when half of the samples with class H and another half with class L. In that sense, the function of deviance is similar to entropy:
The algorithm then uses categorical measures for the generation of clinical decision guideline. At each step, each node was split into two more homogenous subgroups (two children) in an optimal way (i.e. by minimizing the deviance); splitting variables were identified based on an exhaustive search of all possibilities. The tree construction continues until the number of cases reaching each leaf is small (we chose o10) or the leaf is sufficiently homogeneous (we chose 1% of the deviance of the root node). After the tree was grown in its full size (which may be overfitted), we successively snipped off the least important. The importance of a subtree is measured by the following costcomplexity measure
where D k (T) is the deviance of the subtree T, size(T) is the number of terminal nodes of T and k is the cost-complexity parameter that was chosen based on Akaike's information criterion (AIC). 16, 17 For our classification tree, k ¼ 2 minimized the rooted subtree with minimum AIC. 16, 17 One criterion that measures the accuracy of the algorithm is the misclassification rate defined as the number of misclassifications/total number of patients. The lower the misclassification rate is, the more accurate the algorithm. The algorithm was generated using five variables (pre-mobilization therapy blood CD34 þ cells/ml, type of mobilization regimen, diagnosis, age and gender) in the model simultaneously. We also compared CART to more traditional statistical methods such as logistic regression 18 (see below).
Results
The clinical characteristics of the study patients who were included in the analyses are summarized in Table 1 . A total of 142 subjects were analyzed, 106 patients with a wide range of malignancies and 36 human lymphocytic antigenidentical sibling allogeneic donors. The predominant mobilization regimen for the patients was cyclophosphamide and G-CSF (49%), whereas the allogeneic donors received single agent G-CSF. The mean pre-mobilization There was a positive correlation between pre-mobilization therapy blood CD34 þ cell count and post-mobilization CD34 þ cell yield (r ¼ 0.37, Po0.0001). When the allogeneic donors alone are analyzed, the correlation improved, r ¼ 0.56, P ¼ 0.0004 as compared to r ¼ 0.32, P ¼ 0.0008 in patients with malignant diagnoses (Figure 2 ). There was also a stronger correlation between premobilization therapy blood CD34 þ cells Â 10 6 /l and postmobilization therapy blood CD34 þ cell yield in males r ¼ 0.46, Po0.0001 as compared to females r ¼ 0.29,
Despite a good correlation between pre-mobilization therapy blood CD34 þ cell count and post-mobilization therapy CD34 þ cell yield, it was not possible to generate a cutoff point with a high confidence to identify potential mobilization failures. Initially, we employed logistic regression and linear regression, but these approaches failed to identify useful variables and were a poor model fitting to our data. Therefore, we used CART analysis to study multiple variables in predicting successful mobilization in an attempt to generate a classification rule. The algorithm was generated using five variables including pre-mobilization therapy blood CD34 þ cell count Â 10 6 /l, type of mobilization regimen, diagnosis, age and gender in the model simultaneously. The response variable, post-mobilization CD34 þ cell count, was categorized into two levels: high (CD34 þ /kg/leukapheresisX1 Â 10 6 cells) or low (CD34 þ /kg/leukapheresiso1 Â 10 6 cells).
CART analysis revealed that the pre-mobilization therapy blood CD34 þ cell count is the predominant determinant of the CD34 þ cell yield ( Figure 3 ). In the classification tree, root and internal nodes are represented by ellipses and terminal nodes (leaf nodes) are represented by rectangles and labeled by the majority of highs (CD34 þ / kg/leukapheresisX1 Â 10 6 cells) or lows (CD34 þ /kg/leukapheresiso1 Â 10 6 cells). 16, 17 Figure 3 shows the algorithm based on the individuals' characteristics and mainly the pre-mobilization CD34 þ cell count; each node becomes progressively more homogeneous than its parent node. Under each node, the misclassification rate is printed. Further, the analysis quantified that a pre-mobilization therapy blood CD34 /l, the predicted post-mobilization therapy CD34 þ cell yield was high regardless of their age, gender, disease type and mobilization method used. The misclassification rate for these subjects was very low (2%). For those subjects with pre-mobilization therapy blood CD34 þ cell count p2.65 cells Â 10 6 /l, the predicted post-mobilization therapy CD34 þ cell yield was variable with a misclassification rate of 24%. Furthermore, several branches of that subtree were split based on pre-mobilization therapy blood CD34 þ cell count, which further implies the predictive value of pre-CD34 þ counts. þ count, however, was not a linear relationship in predicting the post-CD34 þ as the misclassification rate for those subjects with pre-mobilization therapy blood CD34 þ between 2.35 and 2.65 cells Â 10 6 /l was 44%. Among those who fell into the poor 'mobilizers' category (leaf nodes with label L, see Figure 3 ), 16 of 25 were classified correctly, while nine subjects exhibited good mobilization. As seen from the tree, other factors Figure 2 Higher level of correlation of pre-mobilization therapy blood CD34 þ cell count and post-mobilization therapy CD34 þ cell yield in allogeneic donors vs patients with malignancy.
CD34
þ blood count and mobilization efficacy P Fu et al such as age, disease type and mobilization procedures played important roles as well in the decision rules. The misclassification rate, however, was reduced significantly by additional variables as represented by the nodes in the tree with overall misclassification rate of 16% (Table 2) .
Discussion
We undertook this retrospective analysis in order to identify the best predictive variables for likelihood to mobilize adequate numbers of CD34 þ cells in patients and allogeneic donors. We found that with pre-mobilization Figure 3 Algorithm for predicting post-mobilization of CD34
6 cells). In the tree, circle represents root or internal nodes; and rectangle represents the terminal nodes (leaves). The number and the letter inside the shape (circle or rectangle) represent the node and the majority of patients with that outcome, respectively. The label on each arm is the splitting criterion. The number under each node is the misclassification rate. For leaf nodes, the median (range) of post-mobilization of CD34 þ cell yield (in 10 6 cells) was also put under the node.
Table 2
Statistics related to the tree ( Figure 3 ) Abbreviations: AML ¼ acute myelocytic leukemia; deviance ¼ the measure for impurity; F ¼ female; HD ¼ hemodialysis; MM ¼ multiple myeloma; M ¼ male; n ¼ the size of the node (number of patients in the node); Node ¼ for node number; NHL, non-Hodgkin's lymphoma; split ¼ for splitting criteria; yprob (H, L) ¼ the distribution by class within the node; yval ¼ the value of the majority in the node. a Denotes terminal node (leaf node).
CD34 þ blood count and mobilization efficacy P Fu et al therapy blood CD34
þ cell count, we could predict patients and allogeneic donors at risk for mobilization failure. When combined with easily available patient variables, this number can be used in an algorithm to identify high-risk patients and allogeneic donors. Many reports indicate that infusion of X2.5 Â 10 6 CD34 þ cells/kg provides timely myeloid blood cell recovery after high-dose chemotherapy. 2 The response of individual patients to mobilizing therapies, however, is variable and unpredictable, 19 and 20-50% of patients have poor mobilization. [7] [8] [9] For some patients in whom adequate PBSC cannot be collected, bone marrow harvests have been attempted; morbidity and mortality rates in this group appear increased. 20, 21 Patients failing initial mobilization have been remobilized successfully using escalated doses of G-CSF and combination therapy of G-CSF þ GM-CSF. 21, 22 However, this strategy is very costly and assumes clinically stable disease to allow sufficient time to remobilize patients.
Our data for the entire study population indicate a positive correlation, r ¼ 0.37, between pre-mobilization therapy blood CD34 þ cell count and the yield of progenitor cells that are collected. In the subgroups of both allogeneic donors and males, this correlation was even stronger, r ¼ 0.56 and r ¼ 0.46, respectively. This finding may reflect a more homogeneous group with less variability in baseline blood CD34 þ cell count and uniform preparation. Further, we used five simple clinical variables to develop an algorithm with the CART analysis to identify pre-mobilization therapy blood CD34 þ cell content as the main factor in predicting successful mobilization. The CART analysis is a tree-based method that can uncover complex interactions between variables to help generate a clinical decision rule. For subjects with pre-mobilization therapy blood CD34 þ cell counts 42.65 Â 10 6 /l, regardless of age, gender, disease type and mobilization regimen, the predicted post-mobilization progenitor count was anticipated to exceed 1 Â 10 6 CD34 þ cells/kg/leukapheresis procedure with only a 2% false-positive rate. This threshold blood CD34 þ cell count cutoff must be validated in a multi-institutional setting.
We compared CART with logistic regression treating post-mobilization of CD34
þ /kg/leukapheresiso1 Â 10 6 cells)) as a dichotomized outcome variable. The results using logistic regression show that only pre-mobilization therapy blood CD34 þ cell count and patient type (allogeneic donors vs patients) were significant predictors of patient outcome. Further, the logistic procedures did not fit the data well as R 2 ¼ 0.172 using logistic regression. Owing to the above results in which logistic regression failed to identify useful variables and was a poor model fitting to our data, the objective to generate decision rules, as well as the complexity of our data, we used CART to generate the decision rules.
Several studies have attempted to ascertain factors that can be used to provide accurate prediction of PBSC mobilization. Two studies failed to show age as an independent variable on CD34 þ mobilization. 23, 24 Other trials reported mixed results regarding the influence of the tumor-type diagnosis affecting the ability to mobilize progenitor cells; D'Arena et al. 25 and Sautois et al. 26 noted a lower mobilization capacity in patients with hematological malignancies compared to those with solid tumor types. Schlenk et al., 27 however, observed that 83% of acute leukemia patients were able to mobilize sufficient PBSC for transplantation. The influences of bone marrow infiltration and extent of prior chemotherapy and radiation therapy on PBSC mobilization usually is associated with poor PBSC mobilization. 6, [28] [29] [30] [31] [32] We can only speculate that the premobilization blood CD34
þ cell count represents a surrogate marker for the 'health' of the hematopoietic stem cell pool.
Several groups have reported a positive correlation between pre-mobilization blood CD34 þ cell count and the yield after mobilization. [33] [34] [35] These studies, however, were limited by small numbers of patients, patient populations confined to single disease types and no quantification of threshold pre-mobilization CD34 þ cell count that correlated with successful mobilization. Consequently, it generally is not standard practice to exclude a patient or allogeneic donor from undergoing PBSC mobilization owing to an 'unfavorable' pre-mobilization peripheral blood CD34 þ cell count. Despite identification of some predictors for mobilization, individual patients and allogeneic donors who will mobilize PBSC poorly cannot be accurately identified prospectively. New agents that may provide for more mobilization of PBSC are under study. AMD-3100, an antagonist of the chemokine receptor CXCR4 that acts synergistically with G-CSF, has been demonstrated to mobilize three times more PBSC than G-CSF alone in allogeneic donors. 36 The combination of AMD-3100 and G-CSF was tested against single-agent G-CSF in nonHodgkin's lymphoma and multiple myeloma patients. The combination was superior to G-CSF alone in mobilizing higher numbers of PBSC in 84% of the cases; more than 50% CD34 þ cells were collected in the combination group. 37 Carlo-Stella et al. 38 added recombinant growth hormone to standard G-CSF and chemotherapy in patients previously identified as 'poor mobilizers' after an attempt using chemotherapy plus G-CSF. The addition of recombinant growth hormone resulted in 87% of these patients achieving adequate PBSC collections. 38 The strength of our study is the large number of consecutive patients and allogeneic donors we analyzed as well as inclusion of both hematologic and solid tumor malignancy patients of a wide spectrum of age. Further, the algorithm we developed using CART analysis with five variables is unique in that it provides a prospective means to predict adequate CD34 þ cell collection in patients and allogeneic donors based on pre-mobilization therapy CD34 þ cell count. The main utility of the algorithm is for individuals with pre-mobilization CD34 þ cell counts o2.65 Â 10 6 /l who are at risk of being 'poor mobilizers. ' The algorithm can provide a stepwise approach utilizing multiple individual characteristics in decision making regarding the feasibility of achieving an adequate PBSC mobilization.
Initial mobilization failure is a common clinical problem; our analysis demonstrates a nearly 10% misclassification reduction. In this era of cost-containment, improvements in CD34 þ blood count and mobilization efficacy P Fu et al efficiency are valuable. We believe the algorithm we developed can prospectively identify individuals at risk of not achieving sufficient CD34 þ cells post-mobilization, but the utility of our approach must be validated prospectively in a multicenter study. For those patients who likely will not mobilize adequate PBSC with standard approaches, administration of escalated doses and combination cytokines for autograft or consideration of alternative donor allogeneic transplants should be pursued.
